Genome-Wide DNA Methylation Profiling in 40 Breast Cancer Cell Lines

DNA methylation plays important roles in gene regulation and functions. Aberrant methylation, either hypomethylation or hypermethylation, has been reported to cause various diseases, especially cancers. Breast cancer ranked the fifth according to the number of cancer deaths in the world. To systematically characterize the epigenetic modification in breast cancer, we examined the genome-wide methylation profiling in 40 breast cancer cell lines. We identified a gene signature consisting of 345 differentially methylated genes, which could be used to discriminate estrogen receptor (ER)-negative and ERpositive breast cancer cell lines. This gene signature is promising for diagnosis and therapies of breast cancer. In the follow up functional analysis of this gene signature, three enriched networks could be highlighted. Interestingly, one of these networks contained estrogen receptor, implying its functional importance of ER-centric module. Finally, we examined the correlation between methylation and expression of these breast cancer cell lines. Very few genes showed significant correlation, suggesting that gene expression regulated by methylation is a complex biological process.

[1]  Peter Simpson,et al.  DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. , 2010, American journal of human genetics.

[2]  T. Dryja,et al.  Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. , 1991, American journal of human genetics.

[3]  Ian O Ellis,et al.  Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis , 2005, Modern Pathology.

[4]  P. Laird.  Principles and challenges of genome-wide DNA methylation analysis , 2010, Nature Reviews Genetics.

[5]  Pearlly Yan,et al.  Identifying differentially methylated genes using mixed effect and generalized least square models , 2009, BMC Bioinformatics.

[6]  Jose Russo,et al.  DNA methylation changes in a human cell model of breast cancer progression. , 2010, Mutation research.

[7]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[8]  M. Westerfield,et al.  Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer , 1998, International journal of cancer.

[9]  Rudolf Jaenisch,et al.  DNA hypomethylation leads to elevated mutation rates , 1998, Nature.

[10]  F. Antequera,et al.  Structure, function and evolution of CpG island promoters , 2003, Cellular and Molecular Life Sciences CMLS.

[11]  K. Kendler,et al.  The dystrobrevin-binding protein 1 gene: features and networks , 2009, Molecular Psychiatry.

[12]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[13]  C. Klein,et al.  DNA methylation and gene expression: introduction and overview. , 1997, Mutation research.

[14]  Hansoo Lee,et al.  Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. , 2003, Biochemical and biophysical research communications.

[15]  H. Bayley,et al.  Continuous base identification for single-molecule nanopore DNA sequencing. , 2009, Nature nanotechnology.

[16]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[17]  Peter T. Simpson,et al.  Abstract 162: DNA methylome in familial breast cancer identifies distinct profiles defined by mutation status , 2010 .

[18]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[19]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[20]  James D. Brenton,et al.  Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer , 2008, Human molecular genetics.